ReviewDiscover oncology2025
Research progress of galectins in glioma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASGR2 and CLEC12A as Prognostically Relevant C-Type Lectin Hubs in Glioblastoma.International journal of molecular sciences · 2026Article
- Harnessing innate immunity against glioblastoma microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Galectin, a member of the β-galactoside-binding protein family, is involved in various physiological and pathological processes, including cell adhesion, growth, apoptosis, and immune regulation. Due to its high malignancy, heterogeneity, invasive nature, and resistance to radiotherapy and chemotherapy, no effective treatment has been found for glioma so far. Galectin has been discovered to influence the invasion, migration, angiogenesis, and chemotherapy resistance of glioma, and can also play a significant role in the tumor immunosuppressive microenvironment (TME) by acting on immune cells such as T lymphocytes, macrophages, and myeloid-derived suppressor cells (MDSCs). This review discusses the role of galectin, especially the latest research progress on Gal-1, Gal-3, Gal-8, and Gal-9 in glioma, and proposes the therapeutic potential and challenges of targeting galectin for the treatment of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.